Cary Street Partners Asset Management LLC Biogen Inc. Transaction History

Cary Street Partners Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $3,786 - $4,600	15 Added 100.0%	30 $8,000
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $2,920 - $4,026	15 New	15 $4,000
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $934,136 - $1.11 Million	-4,981 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $105,604 - $133,056	-545 Reduced 9.86%	4,981 $1.05 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $320,205 - $411,511	-1,430 Reduced 20.56%	5,526 $1.33 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $26,318 - $34,321	-93 Reduced 1.32%	6,956 $1.97 Million
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $5.77 Million - $9.24 Million	-22,275 Reduced 75.96%	7,049 $2.44 Million
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $611,748 - $716,698	2,518 Added 9.39%	29,324 $1.96 Million
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $6.33 Million - $9.53 Million	26,806 New	26,806 $1.79 Million

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.6B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Cary Street Partners Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Cary Street Partners Asset Management LLC with notifications on news.